Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06559163 · ClinicalTrials.gov registry record · Phase 2

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

A Phase 2 study of Systemic Lupus Erythematosus, sponsored by Zenas BioPharma (USA).

Recruiting
Registry status
Phase 2
Development phase
190
Enrollment target
20
Study locations

NCT06559163 is a Phase 2 study of Systemic Lupus Erythematosus that is actively recruiting participants, run by Zenas BioPharma (USA). The registered enrollment target is 190 participants, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06559163, a Phase 2 study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by Zenas BioPharma (USA).

RECRUITING
Registry status
Phase 2
Development phase
190 participants
Enrollment target
20
Study locations

Study Summary

This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

Conditions Studied

Systemic Lupus Erythematosus

Interventions

  • DRUG Placebo
  • DRUG Obexelimab

Study Locations (20)

California

  • Sierra Pacific Arthritis and Rheumatology Centers - Fresno
  • California Research Institute - Huntington Park
  • University of California, San Diego - La Jolla

Michigan

  • Henry Ford Hospital - Detroit
  • June DO, PC - Lansing
  • Juno DO, PC - Lansing

Texas

  • Prolato Clinical Research Center (PCRC) - Houston
  • Accurate Clinical Research - Houston
  • Prime Clinical Research - Mansfield - Mansfield

Other

  • CHU de Liege - Liège
  • Medical Center Medtech Services EOOD - Haskovo
  • University Multiprofile Hospital for Active Treatment "Eurohospital Plovdiv" - Plovdiv

Florida

  • Clinical Research of West Florida, Inc - Clearwater
  • Clinical Research of West Florida, Inc. - Tampa

Georgia

  • Emory University - Atlanta

Louisiana

  • Accurate Clinical Research - Lake Charles

North Carolina

  • DJL Clinical Research PLLC - Charlotte

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2024-09-17
Est. Completion 2026-09
Phase Phase 2

Sponsor

Zenas BioPharma (USA)

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06559163

The ClinicalTrials.gov registry entry for NCT06559163 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (50% lower). The listed sponsor is Zenas BioPharma (USA), which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06559163 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Michigan, Texas.

Frequently Asked Questions

What is clinical trial NCT06559163 about?

NCT06559163 is a clinical study titled "A Study of Obexelimab in Patients With Systemic Lupus Erythematosus". This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

What is the current status of trial NCT06559163?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2024-09-17. Estimated completion is 2026-09.

What conditions does trial NCT06559163 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT06559163?

The interventions under investigation include: Placebo (DRUG), Obexelimab (DRUG).

Who is sponsoring clinical trial NCT06559163?

This trial is sponsored by Zenas BioPharma (USA), which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06559163 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Systemic Lupus Erythematosus

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.